[Clinical studies on gabapentin in Switzerland].
Gabapentin is a new antiepileptic for the combination therapy of partial seizures. It was introduced in January 1995 in Switzerland. This article describes briefly the ongoing clinical studies in Switzerland; meanwhile, these multicenter studies are conducted in different countries. An open study will evaluate the number of seizure-free patients under therapy with different dosages of gabapentin as add-on therapy. The efficacy and tolerance of gabapentin will be compared with carbamazepine as monotherapy. The last study examines the efficacy of gabapentin for the treatment of partial seizures in pediatric population.
Shokry
A
A
Parke-Davis/Warner Lambert (Schweiz) AG, Baar.
D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003509:Cyclohexanecarboxylic Acids; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D007223:Infant; D008297:Male; D011788:Quality of Life; D013557:Switzerland; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin
Klinische Studien über Gabapentin in der Schweiz.